

**AHNCI Neurologic Oncology Program Tumor Board**

Friday, January 17, 2019

12:00-1:00 p.m.

Jho Conference Room, 6th Floor, AGH

Join Zoom Meeting

<https://zoom.us/j/519670691>

Meeting ID: 519 670 691

Dial by your location

+1 646 558 8656

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case**  | **De-identified patient** | **Reason** | **Presenter** |
| 1 | MC MRN:  3683198 | 77 y/o female with Recurrent Brain Metastasis, diagnosed 4/2017, with Stage IV, ER positive, PR negative, her 2 Neu positive breast cancer, diagnosed 2011. Disease appears to be stable per MRI Brain 1/15/20. Presenting to review imaging. | TR |
| 2 | CR MRN: 10552420 | 72 y/o male with Diffuse large B-cell CNS Lymphoma, diagnosed 06/28/2016, recurrence 5/2018 on MRI Imaging. Increased enhancement/concern for radiation necrosis noted on MRI Brain 1/10/20. Currently not receiving any treatment, though planning to start Revlimid. Presenting to review imaging. | TR |
| 3 | JW MRN: 11737046 | 52 y/o male with Left frontal brain mass on MRI Brain imaging. He underwent biopsy of his lesion on 10/10/2019 which indicated inflammatory/demyelinating lesion. It demonstrated macrophage (DS68-positive) rich lesion with myelin loss (LFB stain) and relative axonal preservation (neurofilament protein stain). Scattered CD3-positive reactive T-cells present; CD20-positive B-cells are not identified. The patient was placed on a 2 week Decadron course with repeat MRI on 10/23/19 which apparently indicated resolution of lesions, but patient continued with weakness/numbness on right side. MRI on 10/28 which indicated apparent unchanged appearance of several abnormal left cerebral hemisphere as well as right cerebellum lesions. Stable findings on most recent brain MRI on 1/14/2020. Presenting to review imaging and discuss possible diagnosis. | TR |
| 4 | DG MRN:  11592204 | 62 y/o female with Left frontal Anaplastic Astrocytoma, WHO Grade III, MGMT Methylated (per CARIS), IDH Wild type (per CARIS), diagnosed 4/26/2019. Currently on maintenance Temodar. Presenting to review MRI Brain 1/15/20. Post treatment changes vs. tumor progression? | TR |
| 5 | RM MRN:  11171901 | 51 y/o male with Right Temporal Glioblastoma, WHO Grade IV, MGMT Methylated (50.78), IDH Wildtype, diagnosed 7/16/2019. Treatment currently on hold due to CDiff infection. New focus of enhancement noted on MRI Brain 1/14/2020. Presenting to review imaging. | TR |
| 6 | CD MRN:  11821051 | 59 y/o male who presented to OSH with difficulty ambulating and memory issues. CTH was performed which demonstrated brain lesions and patient was subsequently transferred to AGH for further workup. Biopsy completed 1/13/20, final pathology pending. Possible lymphoma? Presenting to discuss path with Dr. Gyure. | TR |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

Objectives

Upon completion of this activity, participants will have a better understanding of decision-making for complex neurologic oncology problems and be armed with clinical pathways to improve care.

Accreditation:

Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians. Allegheny General Hospital designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators: Tulika Ranjan, MD and Stephen Karlovits, MD

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–
will use this **same** number every week to text your attendance

**Today’s SMS Code: RODTAS**

You must text within THREE hours of the tumor board. You will receive a text confirming receipt and then an email to complete the evaluation. Once the evaluation is completed credit is registered.